Meeting Summary: Oregon Immunization Program (OIP) Office Hours - October 7, 2024

- 1. Welcome and Opening Remarks
  - Jill Johnson opened the meeting and welcomed participants. The agenda and logistics for connecting with the OIP Help Desk and listserv were shared. The OIP Help Desk can be reached at 1-800-980-9431 or via email at <u>VFC.help@odhsoha.oregon.gov</u>. Information from past Office Hours sessions can be viewed at <u>OIP Office Hours</u>

#### 2. Announcements

- 30th Anniversary of Vaccines for Children (VFC) Program:
  - The VFC program was celebrated for providing over 508 million vaccinations since its inception. It has saved over \$2.7 trillion in societal costs, reducing vaccine-preventable diseases. OIP wants to thank all immunization partners that have made a contribution to the success of the program. <u>Read the CDC Press Release</u>.
- Webinars and Upcoming Events:
  - Pediatric respiratory virus update webinars will be held on October
    17th and 21st. <u>Register for the webinar here</u>.
  - A Boost Oregon webinar on vaccine hesitancy in BIPOC communities is scheduled for October 15th. <u>Register here</u>.
  - Immunize Oregon is looking for volunteers for a panel discussion on vaccine discussions with patients during their quarterly meeting on November 6th. Interested? Contact Molly Sax for more details at mosax@lhs.org.
- Pertussis Alert:
  - Oregon has reported 614 cases of pertussis this year, with infants being the most affected. Only six mothers among 59 infant cases had received the recommended Tdap vaccination during pregnancy. <u>Read</u> <u>the HAN Alert here</u>. More information on vaccinating pregnant patients can be found on the <u>CDC website</u>.
- FluMist and Self-Administration:
  - The FDA has approved FluMist for home administration, starting in the 2025-26 flu season. This will be available for individuals aged 2-

49 years and will be available through an online pharmacy. Further details will be shared when available <u>Read the FDA announcement</u>.

#### 3. Vaccine Supply Updates

- COVID-19 Vaccine Supply:
  - Erin Corrigan updated participants on the distribution of COVID-19 vaccines, highlighting the limited supply of Moderna's Spikevax with less than 10% of requested doses received from the CDC. Vaccines for both adults and pediatric populations are being allocated gradually, with flexibility for use under certain conditions.
- Beyfortus (RSV):
  - Providers were reminded to draw down allocated doses of Beyfortus (RSV) as unclaimed doses will be taken back and reallocated.
     <u>Nirsevimab (Beyfortus) Administration Guide</u>.
- **COVID-19 Vaccines:** Nick provided update on vaccine storage- Only the Children's Pfizer vaccine still needs to be stored at ultra-cold temperatures. The refrigeration time for the Moderna Spikevax vaccine has been doubled from 30 to 60 days.
- Helpful Fall Vaccine Clinical Resources
  - <u>Timing and administration of respiratory season vaccines graphic</u> (CDC)
  - Nirsevimab (Beyfortus) Administration Guide (AAP)

# 4. Protocol Updates

- Pneumococcal Vaccine (PCV-21):
  - The PCV-21 vaccine is now available for adults aged 19 and older who are eligible to receive PCV vaccine due to age or risk factors.
- Meningococcal Vaccine (Bexsero):
  - A new two-dose schedule for Bexsero has been approved by the FDA.
    Doses should now be given 6 months apart. Updates to be made pending further ACIP recommendations.
- RSV Vaccines:

 One dose of RSV vaccine is now recommended for adults aged 75 and older, and for those 60-74 at increased risk of severe illness.
 Pregnant individuals should not receive more than one dose of RSV vaccine. Instead, babies born to mothers who received RSV vaccine during a previous pregnancy should receive Nirsevimab.

### • Flu and COVID-19 Vaccines:

 The flu vaccine for 2024-25 is trivalent, and the new COVID-19 vaccine formulations are approved for use. Most people will require only one dose of the updated COVID vaccine unless they are a child without a complete initial series, are immunocompromised or receiving Novavax. <u>OIP Immunization Protocols</u>.

#### 5. Questions and Discussions

- Vaccine Administration Issues:
  - Participants raised various questions regarding vaccine protocols, calibration of temperature monitoring equipment, and handling private vaccine stocks. Discussions also covered screening forms for flu and COVID vaccines. The CDC's screening forms for all vaccines now include COVID-19 vaccines. <u>Flu Vaccine Contraindications and Screen for Contraindications and Precautions</u>.

## 6. Closing Remarks

• The session ended with Jill Johnson thanking the participants and reminding them of the next Office Hours session on October 21, where Dr. Sutton would discuss respiratory season trends.